Novavax stock rallied by about 5% over the last week, outperforming the S&P 500 which gained less than 1% over the same period. Although Novavax doesn't have a revenue-generating product just yet, with the company intending to file for Emergency Use Authorization for its Covid-19 vaccine in the U.K.
Novavax stock rallied by about 5% over the last week, outperforming the S&P 500 which gained less than 1% over the same period. Although Novavax doesn't have a revenue-generating product just yet, with the company intending to file for Emergency Use Authorization for its Covid-19 vaccine in the U.K.
Share this Article
Recommended